Recently reported data from a multicenter international study on the efficacy and safety of erythropoietin (EPO) treatment in AIHA revealed that the majority of the 51 included patients had inadequate reticulocytosis and reduced endogenous EPO levels considering the degree of anemia displayed. The gene discussed is EPO; the disease is autoimmune hemolytic anemia.